Cellular and Molecular Biology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Department of Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
J Cell Physiol. 2019 Aug;234(10):16724-16738. doi: 10.1002/jcp.28490. Epub 2019 Mar 25.
Codelivery is a promising strategy of targeted delivery of cytotoxic drugs for eradicating tumor cells. This rapidly growing method of drug delivery uses a conjugate containing drug linked to a smart carrier. Both two parts usually have therapeutic properties on the tumor cells. Monoclonal antibodies and their derivatives, such as Fab, scFv, and bsAb due to targeting high potent have now been attractive candidates as drug targeting carrier systems. The success of some therapeutic agents like small interfering RNA (siRNA), a small noncoding RNAs, with having problems such as enzymatic degradation and rapid renal filtration need to an appropriate carrier. Therefore, the aim of this study is to review the recent enhancements in development of antibody drug conjugates (ADCs), especially antibody-siRNA conjugates (SRCs), its characterizations and mechanisms in innovative cancer therapy approaches.
共递药是一种有前途的靶向输送细胞毒性药物以消灭肿瘤细胞的策略。这种快速发展的药物输送方法使用包含药物与智能载体连接的缀合物。这两部分通常对肿瘤细胞都具有治疗特性。由于具有靶向高效的特性，单克隆抗体及其衍生物，如 Fab、scFv 和 bsAb，现已成为有吸引力的药物靶向载体系统候选物。一些治疗剂（如小干扰 RNA（siRNA），一种小的非编码 RNA）的成功，由于存在酶降解和快速肾滤过等问题，需要合适的载体。因此，本研究旨在综述抗体药物偶联物（ADCs），特别是抗体-siRNA 偶联物（SRCs）的最新进展，及其在创新癌症治疗方法中的特性和作用机制。
